Mergers & Acquisitions ·
Adial Pharmaceuticals, Inc. filed an amendment to its Form 8-K to include the historical and pro forma financial…
ADILAzora Therapeutics, Inc. (DE)
Adial Pharmaceuticals, Inc. filed an amendment to its Form 8-K to include the historical and pro forma financial statements required for its acquisition of Azora Therapeutics, Inc., which closed on June 11, 2026. In exchange for all shares of Azora, Adial issued 437,421 common shares and Series A Non-Voting Convertible Preferred Stock convertible into 12,930,617 common shares. Concurrently, Adial raised approximately $26.8 million in gross proceeds from a PIPE financing by issuing pre-funded warrants to purchase 9,749,345 shares at $2.7489 per warrant. The transaction also involved the extinguishment of $5.5 million of Azora's convertible promissory notes via exchange agreements for additional warrants. Adial Pharmaceuticals operates in the biopharmaceutical industry.